Skip to main content
SpringerLink
Log in

Challenges and Opportunities in the Chinese Herbal Drug Industry

  • Chapter
Natural Products

Abstract

Tremendous achievements have been made in Western medicine in the past that provide fast relief of symptoms at the disease sites, particularly under critical conditions. However, some are either ineffective or produce undesirable adverse effects, or are too costly in some complex diseases, especially chronic diseases. On the other hand, traditional medicines strive to focus on the balance of the body in a holistic manner. Traditional medicines are increasing popular in the Western world, as reflected in the name changes from “alternative medicines” to “complementary medicines” or even “integrative medicines.” Traditional Chinese medicines (TCM) have been used in China for more than 2000 yr and have always followed the philosophy and principle of restoration, i.e., the yin and yang (balance of the body). As an important part of the pharmaceutical sector, the Chinese herbal drug industry has made rapid progress over the past decades. This chapter provides a review of its current status, including challenges and opportunities, specifically with regard to modernization and globalization of TCM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100(13):7977–7982.

    PubMed  CAS  Google Scholar 

  2. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1, 117–123.

    PubMed  CAS  Google Scholar 

  3. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287, 1969–1973.

    PubMed  CAS  Google Scholar 

  4. Lenz GR, Nash HM, Jindal S. Chemical ligands, genomics and drug discovery. Drug Discovery Today 2000;5, 145–156.

    PubMed  CAS  Google Scholar 

  5. Kalgutkar AS, Crews BC, Rowlinson SW., et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 2000;97:925–930.

    PubMed  CAS  Google Scholar 

  6. Nanda A, St. Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004;16:44–49.

    PubMed  CAS  Google Scholar 

  7. Review of Global Pharmaceutical Industry in 2002. Institute of the South Economic Research of SFDA, 2003.

    Google Scholar 

  8. Service RF. Surviving the blockbuster syndrome. Science 2004;303(5665):1796–1799.

    PubMed  Google Scholar 

  9. Lathers CM. Challenges and opportunities in animal drug development: a regulatory perspective. Nat Rev Drug Discov 2003;2(11):915–918.

    PubMed  CAS  Google Scholar 

  10. Szuromi P, Vinson V, Marshall E. Rethinking drug discovery. Science 2004:1795.

    Google Scholar 

  11. Knight V, Sanglier JJ, DiTullio D, et al. Diversifying microbial natural products for drug discovery. Appl Microbiol Biotech 2003;62:446–458.

    CAS  Google Scholar 

  12. Landers P. Cost of developing a new drug increases to about $1.7 billion. The Wall Street Journal 12/8/2003.

    Google Scholar 

  13. Kennedy D. Drug discovery. Science 2004;303(5665):1729.

    PubMed  Google Scholar 

  14. Kitano H. Systems biology: a brief overview. Science. 2002;295, 1662–1664.

    PubMed  CAS  Google Scholar 

  15. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res 2002;30:42–46.

    PubMed  CAS  Google Scholar 

  16. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355–365.

    PubMed  CAS  Google Scholar 

  17. Brent R. Genomic biology. Cell 2000;100:169–183.

    PubMed  CAS  Google Scholar 

  18. Kitano H. Computational systems biology. Nature 2002;420(6912):206–210.

    PubMed  CAS  Google Scholar 

  19. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303(5665): 1813–1818.

    PubMed  CAS  Google Scholar 

  20. Shaheen RM, Tseng WW, Davis DW, et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001;61:1464–1468.

    PubMed  CAS  Google Scholar 

  21. Zhang P. Cell cycle control and development: redundant roles of cell cycle regulators. Curr Opin Cell Biol 1999;11:655–662.

    PubMed  CAS  Google Scholar 

  22. Chan-Hui PY. From PGx to molecular diagnostics and personalized medicine. Drug Discov Today 2003;8(18):829–831.

    PubMed  Google Scholar 

  23. Van Haselen RA, Reiber U, Nickel I, Jakob A, Fisher PA. Providing complementary and alternative medicine in primary care: the primary care workers’ perspective. Complement Ther Med 2004;12(1):6–16.

    PubMed  Google Scholar 

  24. Giordano J, Boatwright D, Stapleton S, Huff L. Blending the boundaries: steps toward an integration of complementary and alternative medicine into mainstream practice. J Altern Complement Med 2002;8(6):897–906.

    PubMed  Google Scholar 

  25. McClure MW. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. World J Urol 2002;20(5):273–284.

    PubMed  Google Scholar 

  26. Hong CD. Complementary and alternative medicine in Korea: current status and future prospects. J Altern Complement Med 2001;7:S33–S40.

    PubMed  Google Scholar 

  27. Dossey BM. Holisitic nursing: taking your practice to the next level. Nurs Clin North Am 2001;36(1):1–22.

    PubMed  CAS  Google Scholar 

  28. Larson L. Natural selection. Trustee 2001;54(4):6–12.

    Google Scholar 

  29. Norred CL, Zamudio S, Palmer SK. Use of complementary and alternative medicines by surgical patients. AANA J 2000;68(1):13–18.

    PubMed  CAS  Google Scholar 

  30. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. J Am Med Assoc 1998;280:1569–1575.

    CAS  Google Scholar 

  31. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001;135:262–268.

    PubMed  CAS  Google Scholar 

  32. Goldbeck-Wood S, Dorozynski A, Lie LG, et al. Complementary medicine is booming worldwide. Br Med J 1996;313:131–133.

    Google Scholar 

  33. Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol 2004;43(1):27–34.

    PubMed  Google Scholar 

  34. Engel LW, Straus SE. Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov 2002;1(3):229–237.

    PubMed  CAS  Google Scholar 

  35. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002;137(11):889–903.

    PubMed  Google Scholar 

  36. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prods 1997;60:52–60.

    CAS  Google Scholar 

  37. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66(7):1022–1037.

    PubMed  CAS  Google Scholar 

  38. Mendelson R, Balick MJ. The value of undiscovered pharmaceuticals in tropical forests. Econ Bot 1995;49:223–228.

    Google Scholar 

  39. Dictionary of Natural Products. Chapman and Hall/CRC, London: 2001.

    Google Scholar 

  40. Henkel T, Brunne RM, Müller H, Reichel F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed Engl 1999;38:643–647.

    CAS  Google Scholar 

  41. Berdy J. Are actinomycetes exhausted as a source of secondary metabolites? Proc. 9th Internat Symp Biol Actinomycetes, Part 1. Allerton, New York: 1995; pp. 3–23.

    Google Scholar 

  42. Roessner CA, Scott AI. Genetically engineered synthesis of natural products: from alkaloids to corrins. Ann Rev Microbiol 1996;50:467–490.

    CAS  Google Scholar 

  43. Fenical W, Jensen PR. Marine microorganisms: a new biomedical resource. In: Attaway DH, Zaborsky OR (eds), Marine Biotechnology I: Pharmaceutical and Bioactive Natural Products. Plenum, New York: 1993; pp. 419–475.

    Google Scholar 

  44. Kiefer DM. A century of pain relief. Todays Chem Work 1997;6(12):38–42.

    Google Scholar 

  45. Clark AM. Natural products as a resource for new drugs. Pharm Res 1996;13:1133–1141.

    PubMed  CAS  Google Scholar 

  46. Tyler VE, Brady LR, Robbers JE. Pharmacognosy, 9th edn. Lea & Febiger, Philadelphia: 1988.

    Google Scholar 

  47. Schultz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician’s Guide to Herbal Medicine, 4th edn. Springer, Berlin: 2001.

    Google Scholar 

  48. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985;228: 1049–1055.

    PubMed  CAS  Google Scholar 

  49. Horwitz SB. Personal recollections on the early development of taxol. J Nat Prod 2004;67(2): 136–138.

    PubMed  CAS  Google Scholar 

  50. Clark J. Regulation of natural health products challenged. CMAJ. 2004;170(8):1217.

    PubMed  Google Scholar 

  51. Blumenthal M. In: Blumenthal M et al (eds), The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines 17. Austin, Texas: American Botanical Council, 1998.

    Google Scholar 

  52. Unschuld PU. The past 1000 years of Chinese medicine. Lancet 1999;354 Suppl:SIV9.

    Google Scholar 

  53. Opara EI. The efficacy and safety of Chinese herbal medicines. Br J Nutr 2004;91(2):171–173.

    PubMed  CAS  Google Scholar 

  54. Kam PC, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia 2002; 57(11):1083–1089.

    PubMed  CAS  Google Scholar 

  55. Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002;252(2):107–113.

    PubMed  CAS  Google Scholar 

  56. Normile D. Asian medicine. The new face of traditional Chinese medicine. Science 2003; 299(5604):188–190.

    PubMed  CAS  Google Scholar 

  57. Lampert N, Xu Y. Chinese herbal nephropathy. Lancet 2002;359(9308):796–797.

    PubMed  Google Scholar 

  58. Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ 1997;315(7100):115–117.

    PubMed  CAS  Google Scholar 

  59. Wang ZG, Ren J. Current status and future direction of Chinese herbal medicine. Trends Pharmacol Sci 2002;23(8):347–348.

    PubMed  CAS  Google Scholar 

  60. Bodeker G. Lessons on integration from the developing world’s experience. BMJ 2001; 322(7279):164–167.

    PubMed  CAS  Google Scholar 

  61. Scheid V. The globalization of Chinese medicine. Lancet 1999;354 Suppl:SIV10.

    Google Scholar 

  62. Research Report of Chinese Pharmaceutical Market Analysis of Chinese Herbal Drug Industry, WAN Fang Database Co. Ltd., 2003.

    Google Scholar 

  63. Summary of Chinese Herbal Pharmaceutical Technology and Process. Information Center of State Drug Administration, 2002.

    Google Scholar 

  64. Liu ZH, Li ZJ. The Industrial Developing Strategy of Chinese Herbal Drug Modernization. Traditional Chinese Medicine, Beijing: 2003.

    Google Scholar 

  65. Chinese Medicines and Health Products Report. Ming Jing Market Research & Consultation Co., Ltd., 2002.

    Google Scholar 

  66. Developing and Future Trend of National and International Pharmaceutical Industry in 2002. Institute of Economic Research of NDRC, 2003.

    Google Scholar 

  67. Huang LQ, Cui GH, Chen ML, et al. Study on complex system of Chinese material medica GAP fulfilling-the situation, problems, and prospects of Chinese material medica germplasm. China J Chin Mate Med 2002;27:481–483.

    Google Scholar 

  68. Huang LQ, Cui GH, Dai RW. Study on complex system of Chinese Materia Medica GAP fulfilling. China J Chin Mater Med 2002;27:1–3.

    CAS  Google Scholar 

  69. Yuan CQ, Wang NH, Lu Y. Conservation of endangered medicinal plants in China. In: Zhang ED, Zheng HC (eds), Conservation of Endangered Medicinal Wildlife Resources in China. Second Military Medical University Press, Shanghai: 2000; pp. 25–32.

    Google Scholar 

  70. Wang LX, Xiao LL. Significance of medicinal botany to the conservation of endangered species. In: Zhang ED, Zheng HC (eds), Conservation of Endangered Medicinal Wildlife Resources in China. Second Military Medical University Press, Shanghai: 2000; pp. 83–86.

    Google Scholar 

  71. Liu HG, Zhan YH, Chen JC. The cultivation and GAP of Chinese Materia Medica in Hubei province in China. J Hubei College TCM 2001;3:45–46.

    Google Scholar 

  72. Shang MF, Zhu Y. The situation of cultivation base of Chinese materia medica in China. Res Inform Trad Chin Med 2000;2(10):23–27.

    Google Scholar 

  73. Wang WQ, Liu CS, Sun ZR, et al. The study of GAP and its application in Chinese materia medica. Res Inform Trad Chin Med 2001;3(10):14–16.

    Google Scholar 

  74. Wang JM, Liu HM, Jiang CZ, et al. The establishment of GAP cultivation base. Chin Pharm 2002;16:32–34.

    CAS  Google Scholar 

  75. Yao ZG, Fu YQ. Recent questions and improved measures of Chinese Prepared Medicinal Herbs. Lishizhen Mater Med Res 2002;13(9):552–553.

    Google Scholar 

  76. Economic Operating Analytic Report of Pharmaceutical Industry in 2001. Bureau of Economic Operation of SETC, 2002.

    Google Scholar 

  77. Review and Prospect of the Pharmaceutical Companies on the Stock Market. Bureau of Economic Operation of SETC, 2003.

    Google Scholar 

  78. Shao YD, Gao WY, Jia W, et al. The quality control of plan extract. China J Chin Mater Med 2003;28(10):899–903.

    Google Scholar 

  79. Jia W, Gao W Y, Xiao PG. The discussion of internationalization of Chinese herbal drugs. China J Chin Mater Med 2002;27(9):645–648.

    Google Scholar 

  80. Fan QL. Science of Prescription. Shanghai TCM University Press, Shanghai: 2002.

    Google Scholar 

  81. Sasaki H. International Senior Forum of Traditional Chinese Medicines & Botanical Products. Speech Collection: 38-41, Hangzhou, China, 2001.

    Google Scholar 

  82. Lord GM, Cook T, Arlt VM, et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358:1515–1516.

    PubMed  CAS  Google Scholar 

  83. Ma HM, Zhang BL, Xu ZP, et al. Experimental research on the renal toxicity of Guan-mu-tong (Aristolochiae manshuriensis). Clin Pharmacol Tradit Chin Med 2001;12:404–409.

    Google Scholar 

  84. Pub L no. 75-717, 52 Stat 1040 (1938) 21 USC 9 (Food, Drug and Cosmetic Act 1938).

    Google Scholar 

  85. Pub L no. 87-781, § 102(c), 76 Stat 780 (1962) (codified at 21 USC § 355(d) (5)) (Kefauver Harris Amendment of 1962).

    Google Scholar 

  86. Pub L no. 103-417, 108 Stat 4325 (1994) 21 USC 231 (The Dietary Supplement Health and Education Act of 1994).

    Google Scholar 

  87. Bass IS, Raubicheck CJ. Marketing Dietary Supplements. Washington DC: Food and Drug Law Institute, 2000.

    Google Scholar 

  88. Federal Register. House Government Reform Committee. Six Years After the Enactment of DSHEA: The Status of National and International Dietary Supplement Regulation (March 20, 2001).

    Google Scholar 

  89. Qi G. Protective effect of gypenosides on DNAand RNA of rat. Acta Pharmacol Sin 2000;21:1193–1196.

    PubMed  CAS  Google Scholar 

  90. Yun TK. Panax ginseng-a non-organ-specific cancer preventive? Lancet Oncol 2001;2:49–55.

    PubMed  CAS  Google Scholar 

  91. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001;16:S28–S37.

    PubMed  CAS  Google Scholar 

  92. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci 1999;889:157–192.

    PubMed  CAS  Google Scholar 

  93. Zhao X, et al. Effects of ginsenoside of stem and leaf in combination with choline on improving learning and memory of Alzheimer disease. Chin Pharmacol Bull 2000;16:544–547.

    CAS  Google Scholar 

  94. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applicagtions. Altern Ther Health Med 2001;7:70–90.

    PubMed  CAS  Google Scholar 

  95. Gao Y, et al. Effect of allicin on the regulation of VEGF mRNA expression in human hepatocellular carcinomal cells. Chin Pharmacol Bull 2001;17:531–536.

    CAS  Google Scholar 

  96. Xu JP, Rui YC, Li TJ. Antagonistic effects of ginkgo biloba extract on adhesion of monocytes and neutrophils to cultured cerebral microvascular endothelial cells. Zhongguo Yaoli Xue Bao 1999;20:423–425.

    CAS  Google Scholar 

  97. Deng R. General research situation of long-circulation nanoparticles. Chin Pharm J 2001;36:511–513.

    CAS  Google Scholar 

  98. Nie QH, Luo XD, Zhang JZ, Su Q. Current status of severe acute respiratory syndrome in China. World J Gastroenterol 2003;9(8):1635–1645.

    PubMed  Google Scholar 

  99. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol 2000;3(1):24–32.

    PubMed  CAS  Google Scholar 

  100. Koo LC. Concepts of disease causation, treatment and prevention among Hong Kong Chinese: diversity and eclecticism. Soc Sci Med 1987;25(4):405–417.

    PubMed  CAS  Google Scholar 

  101. Bibeau G. From China to Africa: the same impossible synthesis between traditional and western medicines. Soc Sci Med 1985;21(8):937–943.

    PubMed  CAS  Google Scholar 

  102. Wang WK, Wang YY. Biomedical engineering basis of traditional Chinese medicine. Med Prog Technol 1992;18(3):191–197.

    PubMed  CAS  Google Scholar 

  103. Ernst E. Complementary medicine: evidence base, competence to practise and regulation. Clin Med 2003;3(5):481–482.

    PubMed  CAS  Google Scholar 

  104. Ernst E. Herbal medicines put into context. BMJ 2003;327(7420):881–882.

    PubMed  CAS  Google Scholar 

  105. Hohmann N, Koffler K. Risk of adverse reactions from contaminants in Chinese herbal medicines can be minimized by using quality products and qualified practitioners. Int J Environ Health Res 2002;12(1):99–100.

    PubMed  Google Scholar 

  106. Chan TY, Critchley JA. Usage and adverse effects of Chinese herbal medicines. Hum Exp Toxicol 1996;15(1):5–12.

    Article  PubMed  CAS  Google Scholar 

  107. Chan TY. Monitoring the safety of herbal medicines. Drug Saf 1997;17(4):209–215.

    PubMed  CAS  Google Scholar 

  108. Matsumoto K, Mikoshiba H, Saida T. Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine. J Am Acad Dermatol 2003;48(4):628–630.

    PubMed  Google Scholar 

  109. Li XM, Sampson HA. Novel approaches for the treatment of food allergy. Curr Opin Allergy Clin Immunol 2002;2(3):273–278.

    PubMed  Google Scholar 

  110. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134–138.

    PubMed  CAS  Google Scholar 

  111. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000;20(5):374–387.

    PubMed  CAS  Google Scholar 

  112. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002;23:136–139.

    PubMed  CAS  Google Scholar 

  113. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003;84(2-3):187–192.

    PubMed  CAS  Google Scholar 

  114. Zhang BL, Wang YY, Chen RX. Clinical randomized double-blinded study on treatment of vascular dementia by jiannao yizhi granule. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22(8): 577–580.

    PubMed  CAS  Google Scholar 

  115. Chen LC, Chen YF, Chou MH, Lin MF, Yang LL, Yen KY. Pharmacokinetic interactions between carbamazepine and the traditional Chinese medicine Paeoniae Radix. Biol Pharm Bull 2002;25(4):532–535.

    PubMed  CAS  Google Scholar 

  116. Fugh-Berman A, Kronenberg F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol 2003;17(2): 137–152.

    PubMed  CAS  Google Scholar 

  117. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137(10):805–813.

    PubMed  Google Scholar 

  118. Tang JL, Zhan SY, Ernst E. Review of randomised controlled trials of traditional Chinese medicine. BMJ 1999;319(7203):160–161.

    PubMed  CAS  Google Scholar 

  119. Koop CE. The future of medicine. Science 2002;295(5553):233.

    PubMed  CAS  Google Scholar 

  120. Rahman K. Historical perspective on garlic and cardiovascular disease. J Nutr 2001;131(3s): 977S–979S.

    PubMed  CAS  Google Scholar 

  121. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95(7):526–532.

    Article  PubMed  CAS  Google Scholar 

  122. Pappas SG, Jordan VC. Raloxifene for the treatment and prevention of breast cancer? Expert Rev Anticancer Ther 2001;1(3):334–340.

    PubMed  CAS  Google Scholar 

  123. Honig SF. Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Ann NY Acad Sci 2001;949:345–348.

    Article  PubMed  CAS  Google Scholar 

  124. Goldstein SR. The effect of SERMs on the endometrium. Ann NY Acad Sci 2001;949:237–242.

    Article  PubMed  CAS  Google Scholar 

  125. Prout MN. Breast cancer risk reduction: what do we know and where should we go? Medscape Womens Health 2000;5(5):E4.

    PubMed  CAS  Google Scholar 

  126. Osborne MP. Chemoprevention of breast cancer. Surg Clin North Am 1999;79(5):1207–1221.

    PubMed  CAS  Google Scholar 

  127. Goldstein SR. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women’s health. Int J Fertil Womens Med 1999;44(5):221–226.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

    Wei Jia

  2. Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    Lixin Zhang

  3. SynerZ Pharmaceuticals Inc., Lexington, MA

    Lixin Zhang

Authors
  1. Wei Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lixin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

    Lixin Zhang PhD

  2. SynerZ Pharmaceuticals Inc., Lexington, MA

    Lixin Zhang PhD

  3. Charles A. Dana Research Institute (R.I.S.E.), Drew University, Madison, NJ

    Arnold L. Demain PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Jia, W., Zhang, L. (2005). Challenges and Opportunities in the Chinese Herbal Drug Industry. In: Zhang, L., Demain, A.L. (eds) Natural Products. Humana Press. https://doi.org/10.1007/978-1-59259-976-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-976-9_10

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-383-1

  • Online ISBN: 978-1-59259-976-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation